Applying Guideline Updates and Real-World Experience in CLL

Applying Guideline Updates and Real-World Experience in CLL

Friday, December 10, 2021
Webinar -- 7:30 AM ET
https://www.clinicaloptions.com/CLLNCCNAtlanta2021Join1

Agenda

  • Recommended first-line and second-line regimens
    • Current treatment algorithms
    • Key clinical data and mechanisms for each agent class
  • Key variables in deciding between regimens
    • Biomarkers
    • Duration of treatment (fixed duration or continuous treatment)
  • Putting it all together for effective management of CLL
    • Starting systemic therapy in suitable patients
    • Promoting adherence
    • COVID-19 considerations
    • Adverse event profiles and management guides and resources
  • On the horizon: measurable residual disease, CAR T-cell therapy, and other ongoing research areas

Faculty

Program Director
William G. Wierda, MD, PhD

Professor of Medicine
Chief, Section of CLL
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Faculty
Asher Chanan-Khan, MD

Chair, Department of Hematology/Oncology
Mayo Clinic
Jacksonville, Florida

Faculty
Brian Hill, MD, PhD

Director, Lymphoid Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with CLL/SLL.

Target Audience
This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare professionals who care for patients with CLL/SLL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Design treatment plans for treatment-naive and relapsed/refractory CLL/SLL, including consideration of the agent’s toxicity profile, biomarkers, comorbidities, and patient preference
  • Appraise intraclass differences among agents with the similar therapeutic target in CLL/SLL, regarding selectivity, target binding, efficacy, and adverse event profiles
  • Develop strategies to address unique clinical challenges and leverage an understanding of the current data and NCCN Guideline to optimize outcomes for patients with CLL/SLL
  • Evaluate the evolving role of measurable residual disease, allogeneic hematopoietic cell transplant, and CAR T-cell therapy

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

NCCN designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
NCCN designates this educational activity for a maximum of 2.5 contact hours.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 2.5 contact hours (0.25 CEUs) of continuing education credit. UAN: JA4008196-0000-21-100-L01-P

Attention Pharmacists:
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at https://nabp.pharmacy/ to obtain your NABP e-Profile ID.

Physician Assistant Continuing Medical Education
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content will be reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, will be fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.